Seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 1070-1075

  Wang, HaiBo ^a   Cui, Hui ^b   Ding, ZhengRong ^c   Ba, Pian ^d   Zhu, ShuangLi ^a   Wen, Ning ^a   Hao, LiXin ^a   Ning, Jing ^b   Zhang, Jie ^c   Yang, De ^e   Xu, WenBo ^a   Zhang, Yong ^a   Fan, ChunXiang ^a   Yu, WenZhou ^a   Liang, XiaoFeng ^a   Luo, HuiMing ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention   (China)

^c YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Xigaze Prefecture Center for Disease Control and Prevention   (China)

^e Tibet Autonomous Region Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE; POLIOMYELITIS VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CHINA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SEROPREVALENCE; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUTRALIZATION TESTS; POLIOVIRUS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84880482892     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00092-13     Document Type: Article

References (39)

1. CDC. 2011. Progress toward interruption of wild poliovirus transmission - worldwide, January 2010-March 2011. MMWR Morb. Mortal. Wkly. Rep. 60:582-586.
2. CDC. 1999. Progress toward the global interruption of wild poliovirus type 2 transmission, 1999. MMWR Morb. Mortal. Wkly. Rep. 48:736-738, 747.
3. CDC. 2006. Resurgence of wild poliovirus type 1 transmission and consequences of importation - 21 countries, 2002-2005. MMWR Morb. Mortal. Wkly. Rep. 55:145-150.
4. CDC. 2008. Progress toward interruption of wild poliovirus transmission - worldwide, January 2007-April 2008. MMWR Morb. Mortal. Wkly. Rep. 57:489-494.
5. CDC. 2009. Wild poliovirus type 1 and type 3 importations - 15 countries, Africa, 2008-2009. MMWR Morb. Mortal. Wkly. Rep. 58:357-362.
6. CDC. 2010. Progress toward interruption of wild poliovirus transmission - worldwide, 2009. MMWR Morb. Mortal. Wkly. Rep. 59:545-550.
7. CDC. 2010. Outbreaks following wild poliovirus importations - Europe, Africa, and Asia, January 2009-September 2010. MMWR Morb. Mortal. Wkly. Rep. 59:1393-1399.
8. CDC. 2010. Outbreak of poliomyelitis in Tajikistan in 2010: risk for importation and impact on polio surveillance in Europe? Euro Surveill. 15: pii=19558. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19558.
9. CDC. 1999. Progress toward poliomyelitis eradication - Myanmar, 1996-1999. MMWR Morb. Mortal. Wkly. Rep. 48:967-971.
10. CDC. 2000. Wild poliovirus imported into Qinghai province, China. Wkly. Epidemiol. Rec. 75:55-57.
11. CDC. 2000. Importation of wild poliovirus into Qinghai Province - China, 1999. MMWR Morb. Mortal. Wkly. Rep. 49:113-114.
12. Chiba Y, Murakami H, Kobayashi M, Shimizu H, Yoshida H, Yoneyama T, Miyamura T, Jingjin Y, Libi Z. 2000. A case of poliomyelitis associated with infection of wild poliovirus in Qinghai Province, China, in October 1999. Jpn. J. Infect. Dis. 53:135-136.
13. World Health Organization. 1997. Manual for the virological investigation of polio. WHOEPI/GEN/97.01.EPI. World Health Organization, Geneva, Switzerland.
14. CDC. 2012. Progress toward interruption of wild poliovirus transmission - worldwide, January 2011-March 2012. MMWR Morb. Mortal. Wkly. Rep. 61:353-357.
15. CDC. 2006. Outbreak of type-1 wild poliovirus in adults, Namibia, 2006. Wkly. Epidemiol. Rec. 81:425-430.
16. CDC. 2006. Outbreak of polio in adults - Namibia, 2006. MMWR Morb. Mortal. Wkly. Rep. 55:1198-1201.
17. Le Menach A, Llosa AE, Mouniaman-Nara I, Kouassi F, Ngala J, Boxall N, Porten K, Grais RF. 2011. Poliomyelitis outbreak, Pointe-Noire, Republic of the Congo, September 2010-February 2011. Emerg. Infect. Dis. 17:1506-1509.
18. CDC. 2000. Outbreak of poliomyelitis - Cape Verde, 2000. MMWR Morb. Mortal. Wkly. Rep. 49:1070.
19. Prevots DR, Ciofi degli Atti ML, Sallabanda A, Diamante E, Aylward RB, Kakariqqi E, Fiore L, Ylli A, van der Avoort H, Sutter RW, Tozzi AE, Panei P, Schinaia N, Genovese D, Oblapenko G, Greco D, Wassilak SG. 1998. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin. Infect. Dis. 26:419-425.
20. Anonymous. 2010. Poliomyelitis in Tajikistan: first importation since Europe certified polio-free. Wkly. Epidemiol. Rec. 85:157-158.
21. Luchs A, Cilli A, Russo DH, Costa FF, Carmona Rde C, Timenetsky Mdo C. 2010. Monitoring of poliovirus neutralizing antibodies in Sao Paulo State, Brazil. Trans. R. Soc. Trop. Med. Hyg. 104:625-627.
22. Diedrich S, Claus H, Schreier E. 2002. Immunity status against poliomyelitis in Germany: determination of cut-off values in international units. BMC Infect. Dis. 2:2.
23. Bass JW, Halstead SB, Fischer GW, Podgore JK, Wiebe RA. 1978. Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series. JAMA 239:2252-2255. (Pubitemid 8340942)
24. Mastroeni I, Patti AM, Fabrizi A, Santi AL, Manduca AM, Vescia N, Squarcione S, Fara GM. 1997. Immunity status against poliomyelitis in persons 13-14 years old living in Rome. Vaccine 15:747-750. (Pubitemid 27240490)
25. Reali D, Carducci A, Ruschi MA. 1990. Serum antibodies to polioviruses in a Tuscan population, Italy. Eur. J. Epidemiol. 6:309-312. (Pubitemid 20346708)
26. Trivello R, Farisano G, Bonello C, Moschen ME, Baldo V, Majori S, Moretti G, Marin V, Piron L, Renzulli G. 1994. Immunity status to poliovirus in Veneto region (north-east Italy). A seroepidemiological survey. Ann. Clin. Lab. Sci. 24:542-547. (Pubitemid 24332453)
27. Trivello R, Renzulli G, Farisano G, Bonello C, Moschen M, Gasparini V, Benussi G. 1988. Persistence of poliovirus-neutralizing antibodies 2-16 years after immunization with live attenuated vaccine. A seroepidemiologic survey in the mainland of Venice. Epidemiol. Infect. 101:605-609. (Pubitemid 19034450)
28. Lamy ME, Cornu C, Desmyter J. 1979. Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium. Dev. Biol. Stand. 43:207-213. (Pubitemid 10250906)
29. Frantzidou F, Diza E, Halkia D, Antoniadis A. 2005. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin. Microbiol. Infect. 11:68-71. (Pubitemid 40227826)
30. Conyn-Van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T. 2001. Immunity to poliomyelitis in The Netherlands. Am. J. Epidemiol. 153:207-214. (Pubitemid 32958642)
31. Schoub BD, Blackburn NK, McAnerney JM. 2001. Seroprevalence to polio in personnel at a virology institute. J. Infect. 43:128-131. (Pubitemid 33077060)
32. Nates SV, Martinez LC, Barril PA, Ferreyra LJ, Giordano MO, Masachessi G, Isa MB. 2007. Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously. Viral Immunol. 20:3-10. (Pubitemid 46608947)
33. Patriarca PA, Wright PF, John TJ. 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13:926-939.
34. Diedrich S, Claus H, Thierfelder W, Bellach BM, Schreier E. 2000. German health survey 1997/98: immune status against poliomyelitis. Dtsch. Med. Wochenschr. 125:584-588. (In German.) (Pubitemid 30317845)
35. Pirez MC, Olivera I, Diabarboure H, Montano A, Baranano R, Badia F, Bonnet MC. 2009. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: implications for future polio vaccination strategies. Vaccine 27:2689-2694.
36. Arya SC, Agarwal N. 2007. Poliomyelitis: concerns for polio-free countries. Vaccine 25:3245-3246. (Pubitemid 46527983)
37. Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA. 2005. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J. Infect. Dis. 191:990-999. (Pubitemid 40349817)
38. Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. 2007. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro. Surveill. 12:E7-E8.
39. Falleiros-Carvalho LH. 2009. Polio eradication remains a challenge. Vaccine 27:2731-2732.